6533b835fe1ef96bd129f705
RESEARCH PRODUCT
HSP27 : une nouvelle cible pour traiter la fibrose pulmonaire idiopathique ?
F. GoirandPhilippe BonniaudOlivier BurgyL. Pommerollesubject
Pulmonary and Respiratory Medicinemedicine.medical_treatment[SDV]Life Sciences [q-bio]Disease03 medical and health sciencesIdiopathic pulmonary fibrosis0302 clinical medicineHsp27Heat shock proteinmedicine030212 general & internal medicineLungbiologybusiness.industryrespiratory systemmedicine.diseaserespiratory tract diseases3. Good health[SDV] Life Sciences [q-bio]medicine.anatomical_structureCytokine030228 respiratory systembiology.proteinCancer researchFatal diseasebusinessMyofibroblastdescription
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease without therapeutic options. The development of new therapeutic strategies for the disease is needed. IPF is characterized by myofibroblast accumulation and collagen overproduction. Transforming growth factor-β1 (TGF-β1) is a key cytokine activating these pathological processes. Heat shock proteins (HSPs) are crucial regulators and promote TGF-β1 activity. Among them, HSP27 is overexpressed in animal models and in the lung of patients with IPF. HSP27 activates pro-fibrotic mechanisms and therefore may represents a potential target. Strategies aiming to inhibit HSP27 might pave the way towards new treatment options for patients with IPF.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-03-31 |